Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives Average Rating of “Moderate Buy” from Analysts

Akero Therapeutics, Inc. (NASDAQ:AKRO) has been assigned a consensus rating of “Moderate Buy” from the nine ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $41.13.

AKRO has been the topic of a number of research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Akero Therapeutics in a research note on Thursday, June 20th. Wolfe Research assumed coverage on shares of Akero Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Akero Therapeutics in a research report on Monday, August 12th.

Akero Therapeutics Trading Down 2.1 %

NASDAQ AKRO opened at $26.77 on Tuesday. Akero Therapeutics has a 1-year low of $11.25 and a 1-year high of $53.00. The company has a current ratio of 24.89, a quick ratio of 24.89 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $1.86 billion, a PE ratio of -8.37 and a beta of -0.26. The firm’s fifty day simple moving average is $26.09 and its 200-day simple moving average is $23.94.

Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings results on Friday, August 9th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.09. As a group, sell-side analysts anticipate that Akero Therapeutics will post -3.64 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Andrew Cheng sold 1,738 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $26.18, for a total value of $45,500.84. Following the sale, the chief executive officer now directly owns 605,417 shares of the company’s stock, valued at $15,849,817.06. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CEO Andrew Cheng sold 1,738 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $26.18, for a total value of $45,500.84. Following the sale, the chief executive officer now directly owns 605,417 shares of the company’s stock, valued at $15,849,817.06. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Catriona Yale sold 5,200 shares of Akero Therapeutics stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $27.51, for a total value of $143,052.00. Following the sale, the insider now directly owns 75,931 shares in the company, valued at $2,088,861.81. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 276,686 shares of company stock valued at $7,504,883. 7.94% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. raised its stake in shares of Akero Therapeutics by 2,366.0% in the 1st quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock valued at $31,000 after buying an additional 1,183 shares in the last quarter. Quarry LP boosted its holdings in Akero Therapeutics by 40.0% during the fourth quarter. Quarry LP now owns 1,750 shares of the company’s stock valued at $41,000 after purchasing an additional 500 shares in the last quarter. Quest Partners LLC bought a new stake in shares of Akero Therapeutics in the 4th quarter valued at approximately $75,000. Headlands Technologies LLC raised its holdings in shares of Akero Therapeutics by 253.5% in the 1st quarter. Headlands Technologies LLC now owns 4,217 shares of the company’s stock worth $107,000 after buying an additional 3,024 shares in the last quarter. Finally, Ameritas Investment Partners Inc. lifted its position in shares of Akero Therapeutics by 20.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 6,175 shares of the company’s stock worth $156,000 after buying an additional 1,030 shares during the period.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.